Autologous CD19/CD22 dual-target CAR-T cell therapy (Beijing Biotech)

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameAutologous CD19/CD22 dual-target CAR-T cell therapy (Beijing Biotech)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionT lymphocyte replacementsB-lymphocyte antigen CD19 modulatorsCD22 modulators
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsMyelodysplastic SyndromesBone Marrow NeoplasmsNeoplasms, Plasma Cell +[10] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBeijing Biotech
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Biotech
Inactive CompaniesN/A
Active IndicationsMyelodysplastic SyndromesBone Marrow NeoplasmsNeoplasms, Plasma Cell +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A